vs
Planet Labs PBC（PL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Planet Labs PBC的1.6倍（$127.1M vs $81.3M），Planet Labs PBC同比增速更快（32.6% vs 17.1%），Planet Labs PBC自由现金流更多（$1.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 17.5%）
Planet Labs PBC（常简称为Planet）是总部位于美国加利福尼亚州旧金山的上市地球影像企业，核心目标是实现全球范围的每日成像，以此监测地表变化、精准识别相关趋势，为多行业的地理数据分析需求提供可靠的数据支持。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PL vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.6倍
$81.3M
营收增速更快
PL
高出15.5%
17.1%
自由现金流更多
PL
多$28.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
17.5%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $81.3M | $127.1M |
| 净利润 | $-59.2M | — |
| 毛利率 | 57.3% | 51.0% |
| 营业利润率 | -22.6% | -54.6% |
| 净利率 | -72.8% | — |
| 营收同比 | 32.6% | 17.1% |
| 净利润同比 | -194.7% | — |
| 每股收益（稀释后） | $-0.19 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLZLAB
| Q4 25 | $81.3M | $127.1M | ||
| Q3 25 | $73.4M | $115.4M | ||
| Q2 25 | $66.3M | $109.1M | ||
| Q1 25 | $61.6M | $105.7M | ||
| Q4 24 | $61.3M | $108.5M | ||
| Q3 24 | $61.1M | $101.8M | ||
| Q2 24 | $60.4M | $100.1M | ||
| Q1 24 | $58.9M | $87.1M |
净利润PLZLAB
| Q4 25 | $-59.2M | — | ||
| Q3 25 | $-22.6M | $-36.0M | ||
| Q2 25 | $-12.6M | $-40.7M | ||
| Q1 25 | $-35.2M | $-48.4M | ||
| Q4 24 | $-20.1M | — | ||
| Q3 24 | $-38.7M | $-41.7M | ||
| Q2 24 | $-29.3M | $-80.3M | ||
| Q1 24 | $-30.1M | $-53.5M |
毛利率PLZLAB
| Q4 25 | 57.3% | 51.0% | ||
| Q3 25 | 57.6% | 59.5% | ||
| Q2 25 | 55.2% | 60.6% | ||
| Q1 25 | 62.1% | 63.6% | ||
| Q4 24 | 61.2% | 61.5% | ||
| Q3 24 | 52.9% | 64.1% | ||
| Q2 24 | 52.4% | 64.9% | ||
| Q1 24 | 55.2% | 61.4% |
营业利润率PLZLAB
| Q4 25 | -22.6% | -54.6% | ||
| Q3 25 | -24.5% | -42.3% | ||
| Q2 25 | -34.4% | -50.3% | ||
| Q1 25 | -31.5% | -53.3% | ||
| Q4 24 | -36.9% | -62.6% | ||
| Q3 24 | -64.8% | -66.6% | ||
| Q2 24 | -57.2% | -76.0% | ||
| Q1 24 | -57.6% | -80.7% |
净利率PLZLAB
| Q4 25 | -72.8% | — | ||
| Q3 25 | -30.8% | -31.2% | ||
| Q2 25 | -19.1% | -37.3% | ||
| Q1 25 | -57.1% | -45.8% | ||
| Q4 24 | -32.8% | — | ||
| Q3 24 | -63.3% | -40.9% | ||
| Q2 24 | -48.5% | -80.2% | ||
| Q1 24 | -51.1% | -61.4% |
每股收益（稀释后）PLZLAB
| Q4 25 | $-0.19 | $-0.05 | ||
| Q3 25 | $-0.07 | $-0.03 | ||
| Q2 25 | $-0.04 | $-0.04 | ||
| Q1 25 | $-0.12 | $-0.04 | ||
| Q4 24 | $-0.07 | $-0.09 | ||
| Q3 24 | $-0.13 | $-0.04 | ||
| Q2 24 | $-0.10 | $-0.08 | ||
| Q1 24 | $-0.10 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $443.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $349.6M | $715.5M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLZLAB
| Q4 25 | $443.3M | $689.6M | ||
| Q3 25 | $181.1M | $717.2M | ||
| Q2 25 | $133.5M | $732.2M | ||
| Q1 25 | $118.0M | $757.3M | ||
| Q4 24 | $139.0M | $779.7M | ||
| Q3 24 | $148.3M | $616.1M | ||
| Q2 24 | $107.4M | $630.0M | ||
| Q1 24 | $83.9M | $650.8M |
股东权益PLZLAB
| Q4 25 | $349.6M | $715.5M | ||
| Q3 25 | $435.7M | $759.9M | ||
| Q2 25 | $444.8M | $791.7M | ||
| Q1 25 | $441.3M | $810.8M | ||
| Q4 24 | $464.6M | $840.9M | ||
| Q3 24 | $473.2M | $667.7M | ||
| Q2 24 | $500.3M | $704.2M | ||
| Q1 24 | $518.0M | $762.2M |
总资产PLZLAB
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $696.4M | $1.2B | ||
| Q2 25 | $658.4M | $1.2B | ||
| Q1 25 | $633.8M | $1.2B | ||
| Q4 24 | $630.8M | $1.2B | ||
| Q3 24 | $658.4M | $985.3M | ||
| Q2 24 | $674.6M | $987.4M | ||
| Q1 24 | $702.0M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $1.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 2.3% | -21.0% |
| 资本支出强度资本支出/营收 | 32.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $40.7M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PLZLAB
| Q4 25 | $28.6M | $-26.0M | ||
| Q3 25 | $67.8M | $-32.0M | ||
| Q2 25 | $17.3M | $-31.0M | ||
| Q1 25 | $-6.3M | $-61.7M | ||
| Q4 24 | $4.1M | $-55.8M | ||
| Q3 24 | $-7.9M | $-26.8M | ||
| Q2 24 | $-4.3M | $-42.2M | ||
| Q1 24 | $-6.8M | $-90.1M |
自由现金流PLZLAB
| Q4 25 | $1.9M | $-26.7M | ||
| Q3 25 | $47.5M | $-35.0M | ||
| Q2 25 | $9.2M | $-33.9M | ||
| Q1 25 | $-17.9M | $-63.2M | ||
| Q4 24 | $-3.6M | $-58.4M | ||
| Q3 24 | $-23.0M | $-28.2M | ||
| Q2 24 | $-14.2M | $-42.9M | ||
| Q1 24 | $-15.7M | $-91.1M |
自由现金流率PLZLAB
| Q4 25 | 2.3% | -21.0% | ||
| Q3 25 | 64.7% | -30.4% | ||
| Q2 25 | 13.9% | -31.1% | ||
| Q1 25 | -29.1% | -59.9% | ||
| Q4 24 | -5.8% | -53.8% | ||
| Q3 24 | -37.6% | -27.7% | ||
| Q2 24 | -23.6% | -42.9% | ||
| Q1 24 | -26.7% | -104.5% |
资本支出强度PLZLAB
| Q4 25 | 32.9% | 0.5% | ||
| Q3 25 | 27.6% | 2.6% | ||
| Q2 25 | 12.3% | 2.6% | ||
| Q1 25 | 18.9% | 1.5% | ||
| Q4 24 | 12.5% | 2.4% | ||
| Q3 24 | 24.8% | 1.3% | ||
| Q2 24 | 16.4% | 0.7% | ||
| Q1 24 | 15.1% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PL
| Defense And Intelligence | $49.4M | 61% |
| Civil Government | $18.8M | 23% |
| Commercial | $13.1M | 16% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
